USA - NASDAQ:QNRX - US74907L4095 - ADR
Overall QNRX gets a fundamental rating of 1 out of 10. We evaluated QNRX against 534 industry peers in the Biotechnology industry. QNRX may be in some trouble as it scores bad on both profitability and health. QNRX does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -136.54% | ||
| ROE | -476.97% | ||
| ROIC | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.35 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
NASDAQ:QNRX (10/31/2025, 1:56:01 PM)
10.76
-0.66 (-5.78%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.48 | ||
| P/tB | 2.99 | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -136.54% | ||
| ROE | -476.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 | ||
| Altman-Z | -13.35 | 
ChartMill assigns a fundamental rating of 1 / 10 to QNRX.
ChartMill assigns a valuation rating of 1 / 10 to QUOIN PHARMACEUTICALS LT-ADR (QNRX). This can be considered as Overvalued.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a profitability rating of 0 / 10.
The financial health rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 1 / 10.